Distalmotion plans to use the funding to target the U.S. ambulatory surgery center market for its DEXTER robot.
By targeting ambulatory surgery centers, the company is gearing up to compete with Intuitive Surgical for an emerging ...
Distalmotion, the global MedTech company empowering access to the benefits of robotic surgery in outpatient sites of care, today announced the successful closing of its Series G financing round. The ...
Distalmotion announced today that it closed a Series G financing round worth $150 million to support its Dexter surgical robot.
Distalmotion’s Dexter Surgical Robot opens an entirely new era for soft tissue robotics in the outpatient setting and ambulatory surgery centers that will have immediate benefit for patients.
Distalmotion has grabbed hold of a de novo clearance for its Dexter surgical robot, a system designed for hospitals as well as ambulatory surgery centers. The robotic assistant was cleared by the FDA ...
Lausanne, Switzerland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Distalmotion today announced continued momentum in its clinical trial plans to support indication expansion of its DEXTER® Robotic Surgery ...
Lausanne, Switzerland, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Distalmotion has been granted De Novo approval by the U.S. Food and Drug Administration (FDA) to market the Dexter Surgical Robot for adult ...